Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Citi
Covington
Colorcon
Julphar
Mallinckrodt
McKesson
Accenture
UBS

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,964,580

« Back to Dashboard

Summary for Patent: 7,964,580
Title:Nucleoside phosphoramidate prodrugs
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Inventor(s): Sofia; Michael Joseph (Doylestown, PA), Du; Jinfa (New Hope, PA), Wang; Peiyuan (Glen Rock, NJ)
Assignee: Pharmasset, Inc. (Princeton, NJ)
Application Number:12/053,015
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 7,964,580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Try a Free Trial
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Try a Free Trial
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Try a Free Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR ➤ Try a Free Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,964,580

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,906,880 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
8,334,270 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
9,085,573 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
8,580,765 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
8,735,372 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
9,585,906 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
8,957,046 Nucleoside phosphoramidate prodrugs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,964,580

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 201239 ➤ Try a Free Trial
Israel 217228 ➤ Try a Free Trial
Israel 222810 ➤ Try a Free Trial
South Korea 20100016041 ➤ Try a Free Trial
Japan 2010532747 ➤ Try a Free Trial
Japan 5318085 ➤ Try a Free Trial
Japan 2012121903 ➤ Try a Free Trial
Japan 5539419 ➤ Try a Free Trial
Japan 2014196305 ➤ Try a Free Trial
Japan 5774749 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Fish and Richardson
Medtronic
McKesson
Daiichi Sankyo
Moodys
Accenture
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot